Celularity Inc (CELU)

$2.30 +0.10 (4.55%)
Market Cap 50.57M
Revenue (ttm) 22.77M
Net Income (ttm) -196.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -862.10%
Debt to Equity Ratio 2.47
Volume 62,200
Avg Vol 1,385,566
Day's Range N/A - N/A
Shares Out 21.99M
Stochastic %K 64%
Beta 0.62
Analysts Strong Sell
Price Target $16.00

Latest News on CELU

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

Dec 10, 2024, 8:00 AM EST - 5 weeks ago

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023

Dec 6, 2024, 8:00 AM EST - 6 weeks ago

Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023

Celularity Inc. Announces Receipt of Nasdaq Notification

Nov 27, 2024, 5:00 PM EST - 7 weeks ago

Celularity Inc. Announces Receipt of Nasdaq Notification

Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific

Nov 20, 2024, 8:30 AM EST - 2 months ago

Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

Oct 23, 2024, 8:30 AM EDT - 3 months ago

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

Oct 18, 2024, 6:00 PM EDT - 3 months ago

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

Oct 16, 2024, 5:15 PM EDT - 3 months ago

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Sep 5, 2024, 4:05 PM EDT - 4 months ago

Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Celularity Appoints Richard J. Berman to its Board of Directors

Aug 28, 2024, 4:45 PM EDT - 5 months ago

Celularity Appoints Richard J. Berman to its Board of Directors

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Aug 23, 2024, 5:00 PM EDT - 5 months ago

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

Jul 31, 2024, 8:30 AM EDT - 6 months ago

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 3, 2024, 8:38 AM EDT - 8 months ago

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

May 14, 2024, 9:15 AM EDT - 8 months ago

Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

Celularity Inc. to Host Investor and Analyst Research & Development Day

Apr 22, 2024, 8:00 AM EDT - 9 months ago

Celularity Inc. to Host Investor and Analyst Research & Development Day

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Apr 19, 2024, 5:30 PM EDT - 9 months ago

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024

Apr 18, 2024, 4:30 PM EDT - 9 months ago

Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

Apr 15, 2024, 8:00 AM EDT - 9 months ago

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells

Apr 8, 2024, 9:00 AM EDT - 10 months ago

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L

Mar 26, 2024, 9:00 AM EDT - 10 months ago

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

Mar 20, 2024, 9:15 AM EDT - 10 months ago

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit

Mar 14, 2024, 9:15 AM EDT - 11 months ago

Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

Mar 12, 2024, 9:20 AM EDT - 11 months ago

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells

Mar 7, 2024, 9:35 AM EST - 11 months ago

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells

Celularity Announces 1-for-10 Reverse Stock Split

Feb 23, 2024, 4:10 PM EST - 11 months ago

Celularity Announces 1-for-10 Reverse Stock Split

Celularity's Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease

Feb 14, 2024, 4:05 PM EST - 1 year ago

Celularity's Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease

Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline

Feb 1, 2024, 9:00 AM EST - 1 year ago

Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline

Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions

Jan 25, 2024, 9:00 AM EST - 1 year ago

Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions

Celularity Releases CEO Letter to Shareholders

Jan 18, 2024, 1:40 PM EST - 1 year ago

Celularity Releases CEO Letter to Shareholders

Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare

Jan 4, 2024, 1:00 PM EST - 1 year ago

Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare

Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023

Jan 3, 2024, 12:00 PM EST - 1 year ago

Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023

Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification

Oct 18, 2023, 9:00 AM EDT - 1 year ago

Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification

Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

Sep 7, 2023, 4:10 PM EDT - 1 year ago

Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron

Aug 29, 2023, 9:00 AM EDT - 1 year ago

Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron

Celularity Inc. Announces $3 Million Registered Direct Offering

Jul 27, 2023, 9:07 AM EDT - 1 year ago

Celularity Inc. Announces $3 Million Registered Direct Offering

Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications

Jul 27, 2023, 9:00 AM EDT - 1 year ago

Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications

Celularity Human Placental-Derived Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies

Jul 18, 2023, 9:00 AM EDT - 1 year ago

Celularity Human Placental-Derived Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies

Celularity Announces Presentation at Upcoming 7th International Conference on Orthopedics

Jun 29, 2023, 4:05 PM EDT - 1 year ago

Celularity Announces Presentation at Upcoming 7th International Conference on Orthopedics

Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability

Jun 1, 2023, 9:15 AM EDT - 1 year ago

Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability

CELULARITY ANNOUNCES $45 MILLION PURCHASE ORDER, FIRST MIDDLE EAST PRIVATE LABEL AGREEMENT FOR CELULARITY'S HALAL-CERTIFIED BIOMATERIAL PRODUCTS

May 23, 2023, 10:56 AM EDT - 1 year ago

CELULARITY ANNOUNCES $45 MILLION PURCHASE ORDER, FIRST MIDDLE EAST PRIVATE LABEL AGREEMENT FOR CELULARITY'S HALAL-CERTIFIED BIOMATERIAL PRODUCTS

Celularity Announces $45 Million Purchase Order, First Middle East Private Label Agreement For Celularity's Halal-Certified Biomaterial Products

May 23, 2023, 8:10 AM EDT - 1 year ago

Celularity Announces $45 Million Purchase Order, First Middle East Private Label Agreement For Celularity's Halal-Certified Biomaterial Products

Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn's Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation

May 19, 2023, 4:21 PM EDT - 1 year ago

Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn's Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation

Celularity Announces Advisory Guidance From Tamer Group Regarding Anticipated 2023 Purchase Orders for Celularity Branded Halal-Certified Biomaterial Products

May 10, 2023, 9:00 AM EDT - 1 year ago

Celularity Announces Advisory Guidance From Tamer Group Regarding Anticipated 2023 Purchase Orders for Celularity Branded Halal-Certified Biomaterial Products

Celularity Announces Acceptance of Presentation at 26th Annual Meeting of the American Society of Gene and Cell Therapy

May 1, 2023, 4:01 PM EDT - 1 year ago

Celularity Announces Acceptance of Presentation at 26th Annual Meeting of the American Society of Gene and Cell Therapy

Celularity Announces Clinical Data on Human Placental-Derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate Cynk-001 in Adult Patients With Relapsed Refractory and Measurable Residual Disease-Positive Acute Myeloid Leukemia

Apr 27, 2023, 9:00 AM EDT - 1 year ago

Celularity Announces Clinical Data on Human Placental-Derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate Cynk-001 in Adult Patients With Relapsed Refractory and Measurable Residual Disease-Positive Acute Myeloid Leukemia

Celularity's Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like 50™”

Apr 12, 2023, 9:00 AM EDT - 1 year ago

Celularity's Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like 50™”

Celularity Inc. Announces $6 Million Registered Direct Offering

Apr 5, 2023, 9:00 AM EDT - 1 year ago

Celularity Inc. Announces $6 Million Registered Direct Offering

Celularity Announces Acceptance of Poster Presentation at 2023 Society for Biomaterials Annual Meeting

Apr 4, 2023, 9:00 AM EDT - 1 year ago

Celularity Announces Acceptance of Poster Presentation at 2023 Society for Biomaterials Annual Meeting

Celularity Receives U.S. Food And Drug Administration (FDA) Preliminary Assessment For Celularity's Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDA's Center For Devices And Radiological Health

Apr 3, 2023, 9:00 AM EDT - 1 year ago

Celularity Receives U.S. Food And Drug Administration (FDA) Preliminary Assessment For Celularity's Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDA's Center For Devices And Radiological Health

Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the GCC and Egypt

Mar 28, 2023, 10:55 AM EDT - 1 year ago

Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the GCC and Egypt